CoChat
Sign Up
Cited by 282Smoking Behavior and CessationMonoclonal and Polyclonal Antibodies ResearchSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

Open access
Cornuz, Jacques, Zwahlen, Susanne, Jungi, Walter Felix, Osterwalder, Joseph, Klingler, Karl, van Melle, Guy, Bangala, Yolande, Guessous, Idris, Müller, Philipp, Willers, Jörg, Maurer, Patrik, Bachmann, Martin F., Cerny, Thomas·2008·PLoS ONE
DOI 10.1371/journal.pone.0002547PMC PMC2432028
Open this paper in CoChat — free account

Abstract

BACKGROUND: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period. METHODOLOGY/PRINCIPAL FINDINGS: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012). CONCLUSIONS: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction. TRIAL REGISTRATION: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0002547

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow Chart of Study Subjects.
Figure 1 Flow Chart of Study Subjects.CC BY · PubMed Central
Figure 2 Geometric mean nicotine-specific IgG titers (±95% CI) (Active, N = 227; placebo, N = 108).
Figure 2 Geometric mean nicotine-specific IgG titers (±95% CI) (Active, N = 227; placebo, N = 108).CC BY · PubMed Central
Figure 3 Nicotine-specific geometric mean IgG titers (±95 confidence interval) in the per protocol population (N = 229).
Figure 3 Nicotine-specific geometric mean IgG titers (±95 confidence interval) in the per protocol population (N = 229).CC BY · PubMed Central
Figure 4 Point prevalence of smoking abstinence per antibody responder group.
Figure 4 Point prevalence of smoking abstinence per antibody responder group.CC BY · PubMed Central
Figure 5 Mean daily number of cigarettes smoked by non-abstainers per antibody responder group at the respective visit.
Figure 5 Mean daily number of cigarettes smoked by non-abstainers per antibody responder group at the respective visit.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 282

Related

See all

Metadata

Authors
Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Bangala, Y., Guessous, I., Müller, P., Willers, J., Maurer, P., Bachmann, M. F., & Cerny, T.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Kantonsspital St. Gallen (CH)
Corresponding author
Cornuz, Jacques
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2008-06-25
Volume
3
Issue
6
Pages
e2547
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0002547
PMC
PMC2432028
OpenAlex
W2069871552
Cited by
281
References
28
Citations by year
2026: 9 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 15 · 2019: 11 · 2018: 13 · 2017: 21 · 2016: 18 · 2015: 25 · 2014: 14 · 2013: 27 · 2012: 19
FWCI
15.16
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • IRIS (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
nicotine vaccine, smoking cessation, nicotine dependence, tobacco dependence, antibody response, immunotherapy, continuous abstinence, behavioral counseling, vaccine safety
MeSH terms
Adult, Antibody Formation, Double-Blind Method, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Nicotine, Placebos, Vaccines, Smoking Cessation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review